Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2RL3 | Q96RI0 | 6/20 | 0.69 |
| ▸ | LIPG | Q9Y5X9 | 3/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | GLRA3 | O75311 | 1/20 | 0.36 |
| ▸ | LIPC | P11150 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30187688 | 1.00 | F2RL3 (0.69) | F2RL3LIPGPOLBMAPTALDH1A1 | |
| SCHEMBL19783404 | 0.94 | F2RL3 (0.74) | F2RL3LIPGPOLBMAPTGLRA3 | |
| SCHEMBL30189686 | 0.94 | F2RL3 (0.74) | F2RL3LIPGPOLBMAPTGLRA3 | |
| SCHEMBL21379615 | 0.93 | F2RL3 (0.70) | F2RL3LIPGPOLBMAPTGLRA3 | |
| SCHEMBL30189675 | 0.93 | F2RL3 (0.70) | F2RL3LIPGPOLBMAPTGLRA3 | |
| SCHEMBL30189667 | 0.92 | F2RL3 (0.70) | F2RL3LIPGPOLBMAPTGLRA3 | |
| SCHEMBL19783301 | 0.92 | F2RL3 (0.70) | F2RL3LIPGPOLBMAPTGLRA3 | |
| SCHEMBL23463126 | 0.91 | F2RL3 (0.60) | F2RL3LIPGPOLBMAPTALDH1A1 | |
| SCHEMBL19782900 | 0.91 | F2RL3 (0.68) | F2RL3LIPGPOLBMAPTALDH1A1 | |
| SCHEMBL30187762 | 0.91 | F2RL3 (0.68) | F2RL3LIPGPOLBMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190292176-A1 | BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS | BISTOL MYERS SQUIBB COMPANY (US) | 2019-09-26 | — | — | US | disclosed |
| WO-2018013774-A1 | BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190292176-A1 | BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS | F2, F2RL3, PF4 | F2RL3 2/4885LIPG 669/4885POLB 2313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.